New Jersey Assembly Bill A4550

New Jersey 2026-2027 Regular Session

• Introduced: 3/10/26
• Refer: 3/10/26

Caption

Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.

Impact

If enacted, A4550 will have significant implications for state laws governing health insurance coverage, particularly concerning pain management treatments. The legislation will specifically impact contracts provided by health insurers, including hospital service corporations, medical service corporations, health maintenance organizations, and various health benefits plans. Each of these entities will be mandated to adhere to the new standards set forth by this bill, thereby enhancing patient access to crucial pain management therapies.

Summary

Assembly Bill A4550 proposes that health insurers in New Jersey are required to provide coverage for buprenorphine and buprenorphine/naloxone without imposing step therapy or fail-first protocols. This initiative aims to facilitate the access of patients suffering from chronic pain to these medications, which are considered to be less addictive and have a lower potential for abuse compared to other traditional pain medications. By prohibiting insurers from enforcing these protocols, the bill seeks to ensure that patients can directly obtain the necessary treatments that can effectively manage their pain without undergoing potentially harmful prior authorization processes.

Contention

There may be contention surrounding A4550 as it addresses the balance between insurer protocol management and patient rights. Some stakeholders might raise concerns regarding the lack of step therapy as a means to contain costs and evaluate treatment efficacy. Conversely, advocates for patient rights and those representing chronic pain sufferers may laud the legislation for its potential to prioritize patient needs over insurer bureaucratic processes. As public discourse around opioid use and chronic pain management continues, A4550 could become a focal point for debates about the appropriate approaches to pain management and addiction prevention.